epoxyeicosatrienoic acids
lipidEpoxyeicosatrienoic acids are cardioprotective lipid mediators derived from arachidonic acid that promote myocardial repair and inflammation resolution.
Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleCytoprotective eicosanoid; cardioprotection and resolution of cardiac inflammation during myocardial healing.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I33
C — confounder / Type-II68
A — assay feasibility40
E — evidence strength25
T1DI (composite)3
Specificity differential (R−C)-35.1
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only
Literature evidence(2)
- Lipoxygenase drives lipidomic and metabolic reprogramming in ischemic heart failure.Metabolism: clinical and experimental · 2019 · PMID 30999004 · doi
- Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease.Congestive heart failure (Greenwich, Conn.) · 2011 · PMID 21272227 · doi